EGFR and neoplasm: These cancer therapeutic drug nominations (both the heterocyclic chromenes and the sulfur-integrating derivatives) are enabled to inhibit the overexpression of EGFR (epidermal growth factor receptor), which triggers the emergence of numerous tumor subtypes (notably colon, breast, and ovarian).